JP2009511599A - 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 - Google Patents

電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 Download PDF

Info

Publication number
JP2009511599A
JP2009511599A JP2008535728A JP2008535728A JP2009511599A JP 2009511599 A JP2009511599 A JP 2009511599A JP 2008535728 A JP2008535728 A JP 2008535728A JP 2008535728 A JP2008535728 A JP 2008535728A JP 2009511599 A JP2009511599 A JP 2009511599A
Authority
JP
Japan
Prior art keywords
ring
optionally substituted
pain
aliphatic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008535728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511599A5 (enExample
Inventor
エスター マーティンボロー，
ダニエル レーステン，
ティモシー ノイバート，
アルティ サメール カワトカール，
ニコール ジンマーマン，
アンドレアス ターミン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009511599A publication Critical patent/JP2009511599A/ja
Publication of JP2009511599A5 publication Critical patent/JP2009511599A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
JP2008535728A 2005-10-12 2006-10-12 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 Pending JP2009511599A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72568605P 2005-10-12 2005-10-12
PCT/US2006/040156 WO2007047474A2 (en) 2005-10-12 2006-10-12 Biphenyl derivatives as modulators of voltage gated ion channels

Publications (2)

Publication Number Publication Date
JP2009511599A true JP2009511599A (ja) 2009-03-19
JP2009511599A5 JP2009511599A5 (enExample) 2009-11-05

Family

ID=37836784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535728A Pending JP2009511599A (ja) 2005-10-12 2006-10-12 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体

Country Status (15)

Country Link
US (2) US7683083B2 (enExample)
EP (1) EP1934191B1 (enExample)
JP (1) JP2009511599A (enExample)
KR (1) KR20080059292A (enExample)
CN (1) CN101365690A (enExample)
AT (1) ATE551333T1 (enExample)
AU (1) AU2006304283B2 (enExample)
CA (1) CA2624831A1 (enExample)
ES (1) ES2383090T3 (enExample)
IL (1) IL190632A0 (enExample)
NO (1) NO20082165L (enExample)
NZ (1) NZ567570A (enExample)
RU (1) RU2008118350A (enExample)
WO (1) WO2007047474A2 (enExample)
ZA (1) ZA200803704B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
JP2008540539A (ja) * 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
KR20080021030A (ko) * 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
CN101300253B (zh) * 2005-09-09 2012-08-22 沃泰克斯药物股份有限公司 作为电压门控离子通道调控剂的二环衍生物
US7683083B2 (en) * 2005-10-12 2010-03-23 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
CA2626190A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
WO2007075895A2 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
MX2010005307A (es) * 2007-11-13 2010-07-28 Vertex Pharma Derivados heterociclicos como moduladores de canales de iones.
JP2011503112A (ja) * 2007-11-13 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物
WO2009133641A1 (ja) * 2008-04-30 2009-11-05 シャープ株式会社 照明装置、及び表示装置
WO2010002956A2 (en) * 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
CN105026373B (zh) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
US20200270237A1 (en) * 2017-10-19 2020-08-27 Esteve Pharmaceuticals, S.A. New alkoxyamino compounds for treating pain and pain related conditions
CA3105748A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
KR20210019581A (ko) 2018-07-09 2021-02-22 리버 인스티튜트, 아이엔씨 Nav1.8을 억제하기 위한 피리딘 카르복스아미드 화합물
WO2020163236A1 (en) * 2019-02-04 2020-08-13 The General Hospital Corporation Treating long qt syndrome
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534336A (ja) * 2000-05-22 2003-11-18 バイオビトルム アクチボラゲット １１−ベータ−ヒドロキシステロイド・デヒドロゲナーゼタイプ１の阻害因子
JP2005509677A (ja) * 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット １型１１−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤
JP2005509676A (ja) * 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
JP2007501804A (ja) * 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO2002039987A2 (en) * 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7683083B2 (en) * 2005-10-12 2010-03-23 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534336A (ja) * 2000-05-22 2003-11-18 バイオビトルム アクチボラゲット １１−ベータ−ヒドロキシステロイド・デヒドロゲナーゼタイプ１の阻害因子
JP2005509677A (ja) * 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット １型１１−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤
JP2005509676A (ja) * 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
JP2007501804A (ja) * 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
CA2624831A1 (en) 2007-04-26
NZ567570A (en) 2011-02-25
AU2006304283A1 (en) 2007-04-26
US20100130548A1 (en) 2010-05-27
CN101365690A (zh) 2009-02-11
US8236833B2 (en) 2012-08-07
EP1934191B1 (en) 2012-03-28
ATE551333T1 (de) 2012-04-15
NO20082165L (no) 2008-07-09
US7683083B2 (en) 2010-03-23
KR20080059292A (ko) 2008-06-26
US20080113990A1 (en) 2008-05-15
WO2007047474A3 (en) 2007-07-05
IL190632A0 (en) 2008-11-03
ZA200803704B (en) 2009-09-30
ES2383090T3 (es) 2012-06-18
WO2007047474A2 (en) 2007-04-26
EP1934191A2 (en) 2008-06-25
RU2008118350A (ru) 2009-11-20
AU2006304283B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
US7989481B2 (en) Indane derivatives as modulators of ion channels
US8357702B2 (en) Bicyclic derivatives as modulators of voltage gated ion channels
US8236833B2 (en) Biphenyl derivatives as modulators of voltage gated ion channels
EP1888558B1 (en) Bicyclic derivatives as modulators of ion channels
JP2008540539A (ja) イオンチャンネルの調節因子としての二環系誘導体
JP2010539244A (ja) イオンチャネルのモジュレーターとしてのピリジルスルホンアミド
JP2012149084A (ja) イオンチャネルのモジュレーターとして有用なキノリン誘導体
HK1125365A (en) Biphenyl derivatives as modulators of voltage gated ion channels
HK1119433B (en) Indane derivatives as modulators of ion channels
HK1123042A (en) Bicyclic derivatives as modulators of voltage gated ion channels
HK1119434A (en) Bicyclic derivatives as modulators of ion channels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121011